[go: up one dir, main page]

MX2011011272A - Procesos e intermediarios. - Google Patents

Procesos e intermediarios.

Info

Publication number
MX2011011272A
MX2011011272A MX2011011272A MX2011011272A MX2011011272A MX 2011011272 A MX2011011272 A MX 2011011272A MX 2011011272 A MX2011011272 A MX 2011011272A MX 2011011272 A MX2011011272 A MX 2011011272A MX 2011011272 A MX2011011272 A MX 2011011272A
Authority
MX
Mexico
Prior art keywords
processes
intermediates
protease inhibitors
useful
compounds
Prior art date
Application number
MX2011011272A
Other languages
English (en)
Inventor
John E Cochran
Gerald J Tanoury
Minzhang Chen
Valdas Jurkauskas
Adam Looker
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011272(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2011011272A publication Critical patent/MX2011011272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos y procesos de utilidad para la preparación de inhibidores de proteasa, en particular inhibidores de serina proteasa. Los inhibidores de proteasa son de utilidad para el tratamiento de infecciones por HCV.
MX2011011272A 2009-04-27 2010-04-27 Procesos e intermediarios. MX2011011272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/430,207 US8399615B2 (en) 2005-08-19 2009-04-27 Processes and intermediates
PCT/US2010/032556 WO2010126881A1 (en) 2009-04-27 2010-04-27 Processes and intermediates

Publications (1)

Publication Number Publication Date
MX2011011272A true MX2011011272A (es) 2011-11-04

Family

ID=43032514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011272A MX2011011272A (es) 2009-04-27 2010-04-27 Procesos e intermediarios.

Country Status (16)

Country Link
US (2) US8399615B2 (es)
EP (1) EP2477966A1 (es)
JP (1) JP2012525392A (es)
KR (1) KR20120061062A (es)
CN (1) CN102639499A (es)
AU (1) AU2010241800A1 (es)
BR (1) BRPI1013338A2 (es)
CA (1) CA2760163A1 (es)
CL (1) CL2011002657A1 (es)
IL (1) IL215893A0 (es)
MX (1) MX2011011272A (es)
NZ (1) NZ595817A (es)
RU (1) RU2531588C2 (es)
SG (1) SG175800A1 (es)
WO (1) WO2010126881A1 (es)
ZA (1) ZA201108502B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2010008828A2 (en) 2008-06-24 2010-01-21 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
CN102167680B (zh) * 2011-03-23 2014-07-02 合亚医药科技（上海）有限公司 八氢环戊基并[c]吡咯羧酸衍生物的制备方法
IN2014DN08260A (es) 2012-03-16 2015-05-15 Sandoz Ag
ITMI20120990A1 (it) * 2012-06-07 2013-12-08 Dipharma Francis Srl Sintesi di un inibitore delle proteasi virali
IN2014MN02533A (es) * 2012-06-13 2015-07-24 Janssen Pharmaceutica Nv
WO2013189978A1 (en) 2012-06-20 2013-12-27 Sandoz Ag PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR
WO2014102816A1 (en) * 2012-12-26 2014-07-03 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of telaprevir and intermediates
CN103288671B (zh) * 2013-06-20 2014-10-29 上海步越化工科技有限公司 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法
WO2014203208A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and intermediates thereof
CN104558106B (zh) * 2013-10-19 2019-12-10 广东东阳光药业有限公司 一种治疗丙肝药物的制备方法
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
CN105111129A (zh) * 2015-08-24 2015-12-02 上海合全药业股份有限公司 (1S,3aR,6aS)-八氢环戊烯并[C]吡咯-1-羧酸叔丁酯草酸盐的制备方法
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
EP0508307B1 (en) * 1991-04-08 1995-11-29 Sumitomo Chemical Company Limited Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
JPH08151344A (ja) * 1994-09-26 1996-06-11 Nagase & Co Ltd ２−（３−ベンゾイルフェニル）プロピオン酸の光学分割方法
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
JPH0967344A (ja) 1995-09-05 1997-03-11 Koei Chem Co Ltd 光学活性ｎ−ベンジルオキシカルボニルピペコリン酸の製造方法
CA2254122A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
GB9614804D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd Resolution process
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
UA66767C2 (uk) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
US6183121B1 (en) 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
ATE346035T1 (de) 1998-03-31 2006-12-15 Vertex Pharma Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
US6117639A (en) 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
US20020042046A1 (en) 1999-02-25 2002-04-11 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
JP2003525294A (ja) 2000-02-29 2003-08-26 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Ｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害剤
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
ES2317900T3 (es) 2000-04-05 2009-05-01 Schering Corporation Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2.
PL358591A1 (en) 2000-04-19 2004-08-09 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
JP4452441B2 (ja) 2000-07-21 2010-04-21 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
CN102206247B (zh) 2000-07-21 2013-03-27 默沙东公司 一种具有HCV NS3/NS4a蛋白酶抑制活性的化合物
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
CA2429359A1 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
EP1356123A2 (en) 2001-01-30 2003-10-29 Vertex Pharmaceuticals Incorporated A quantitative assay for nucleic acids
CA2441688C (en) 2001-03-27 2014-01-21 Vertex Pharmaceuticals Incorporated Compositions and methods useful for hcv infection
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
WO2003006490A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
JP4460294B2 (ja) 2001-10-24 2010-05-12 バーテックス ファーマシューティカルズ インコーポレイテッド 縮合環系を組み込んだ、セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
MXPA04009938A (es) 2002-04-11 2004-12-13 Vertex Pharma Inhibidores de serina proteasas, en particular la proteasa ns3-ns4a del hcv.
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20050090450A1 (en) 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1613620A1 (en) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NZ544789A (en) 2003-07-18 2010-01-29 Vertex Pharma Dithia-azaspiro-nonane and decane derivatives as inhibitors of serine proteases
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
JP2007505603A (ja) 2003-09-12 2007-03-15 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド プロテアーゼ活性および肝障害のための動物モデル
AU2004274468B2 (en) 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
DE602004031298D1 (de) * 2003-09-26 2011-03-17 Schering Corp Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
MXPA06004006A (es) 2003-10-10 2006-06-28 Vertex Pharma Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c.
AR045870A1 (es) 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CA2551074A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
ATE416789T1 (de) 2003-10-27 2008-12-15 Vertex Pharma Kombinationen für die hcv-behandlung
US7250520B2 (en) 2003-10-28 2007-07-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrroles
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1737821B1 (en) 2004-02-27 2009-08-05 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
JP4898658B2 (ja) 2004-03-12 2012-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体
US7625390B2 (en) 2004-04-16 2009-12-01 Cook Incorporated Removable vena cava filter
JP2008501802A (ja) 2004-06-08 2008-01-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド 医薬組成物
EP1804821A4 (en) 2004-10-01 2009-07-15 Vertex Pharma INHIBITION OF HCV NS3-NS4A PROTEASE
MY141025A (en) 2004-10-29 2010-02-25 Vertex Pharma Dose forms
EP2256113A1 (en) 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN102382170A (zh) 2005-08-19 2012-03-21 弗特克斯药品有限公司 用于制备蛋白酶抑制剂的方法和中间体
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CN101489557B (zh) 2006-02-27 2013-12-18 弗特克斯药品有限公司 包含vx-950的共晶体和包含所述共晶体的药物组合物
EP2407448A3 (en) 2006-03-16 2012-07-25 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
AU2007226984B2 (en) 2006-03-20 2013-02-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
MX2008013796A (es) 2006-04-26 2009-03-31 Vertex Pharma Biomarcadores de infeccion por el virus de hepatitis c.
DE602007009230D1 (de) 2006-05-31 2010-10-28 Vertex Pharma Orale formulierungen mit kontrollierter freisetzung eines interleukin-1-beta-converting-enzyme inhibitors
US20100216161A1 (en) 2009-02-26 2010-08-26 Vertex Pharmaceuticals Incorporated Method for identifying protease inhibitors
MX2009006806A (es) 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
US9005889B2 (en) 2007-01-16 2015-04-14 The Johns Hopkins University Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor
WO2008106151A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8575208B2 (en) 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
EP2157974A1 (en) 2007-05-21 2010-03-03 Vertex Pharmceuticals Incorporated Dose forms comprising vx- 950 and their dosage regimen
CA2704284A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP2214682A2 (en) 2007-11-05 2010-08-11 Vertex Pharmaceuticals Incorporated Hcv combination therapies comprising vx-950, peg-ifn and ribavirin
MX2010011580A (es) 2008-04-23 2010-11-09 Vertex Pharma Tratamiento de infecciones por virus de hepatitis c con telaprevir (vx-950) en pacientes que no responden al tratamiento con interferon-alfa-2a-2b pegilado y ribavirina.
EP2303858A1 (en) 2008-07-03 2011-04-06 Vertex Pharmceuticals Incorporated Preparation of protected alpha-keto beta-amino esters and amides
CN102316935A (zh) 2008-09-24 2012-01-11 弗特克斯药品有限公司 用于治疗肝炎的包含聚乙二醇化干扰素、利巴韦林和vx-950的治疗方案
EP2358439A1 (en) 2008-11-05 2011-08-24 Vertex Pharmaceuticals Incorporated Methods for treating hepatitis c virus infection
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
CA2788348A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
EP2593105A1 (en) 2010-07-14 2013-05-22 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition comprising vx-950
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950

Also Published As

Publication number Publication date
BRPI1013338A2 (pt) 2016-03-29
US20100063252A1 (en) 2010-03-11
CL2011002657A1 (es) 2012-05-25
NZ595817A (en) 2014-03-28
EP2477966A1 (en) 2012-07-25
RU2531588C2 (ru) 2014-10-20
KR20120061062A (ko) 2012-06-12
IL215893A0 (en) 2012-01-31
SG175800A1 (en) 2011-12-29
CA2760163A1 (en) 2010-11-04
JP2012525392A (ja) 2012-10-22
WO2010126881A1 (en) 2010-11-04
ZA201108502B (en) 2012-08-29
AU2010241800A1 (en) 2011-12-01
US8399615B2 (en) 2013-03-19
US8871904B2 (en) 2014-10-28
CN102639499A (zh) 2012-08-15
US20130172276A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
MX2011011272A (es) Procesos e intermediarios.
WO2007022459A3 (en) Processes and intermediates
AP2009004971A0 (en) Inhibitors of serine proteases for the treatment of HCV infections
WO2011002808A8 (en) Hcv protease inhibitors and uses thereof
MY153766A (en) Derivatised proline containing peptide organic compounds as protease inhibitors
SG179566A1 (en) Hcv protease inhibitors
HUS1700039I1 (hu) Makrociklusos prolinból leszármaztatható HCV szerin proteáz inhibitorok
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
TN2011000673A1 (en) Bace inhibitors
WO2012004678A3 (en) Serine protease inhibitors
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2014001944A (es) Formas cristalinas de un inhibidor de la proteasa del virus de la hepatitis c.
WO2013074386A3 (en) Hcv ns3 protease inhibitors
TN2014000079A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
EP3486319A3 (en) Compositions and methods comprising serine protease variants
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
MX345259B (es) Inhibidores de serina proteasas similares a tripsina, y su preparación y uso.
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
PT2382198E (pt) Processos e intermediários para a preparação de um inibidor macrocíclico de protease do vhc
WO2012019299A9 (en) Hepatitis c inhibitor compounds

Legal Events

Date Code Title Description
FG Grant or registration